| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4392279 | F | Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 2. | ALA4392280 | B | Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes measured after 1 hr | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 3. | ALA4392281 | A | Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 4. | ALA4392282 | A | Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 5. | ALA4392283 | B | Selectivity ratio of EC50 for recombinant human V1a receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 6. | ALA4392284 | B | Selectivity ratio of EC50 for recombinant human V1b receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells | Homo sapiens | 9 | cell-based format | Scientific Literature | ||
| 7. | ALA4392285 | F | Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method relative to oxytocin | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 8. | ALA4392287 | F | Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as latency time to retrieve pups by sires at 100 ng/ml, ip administered as single dose measured after 30 mins by parental retrieval test (Rvb = 600 sec) | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 9. | ALA4392289 | F | Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as latency time to retrieve pups by sires at 100 ng/ml, ip administered as single dose measured after 5 hrs by parental retrieval test (Rvb = 233 +/- 68 sec) | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 10. | ALA4392290 | F | Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as latency time to retrieve pups by sires at 100 ng/ml, ip administered as single dose measured after 12 hrs by parental retrieval test (Rvb = 233 +/- 68 sec) | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 11. | ALA4392291 | F | Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as latency time to retrieve pups by sires at 100 ng/ml, ip administered as single dose measured after 24 hrs by parental retrieval test (Rvb = 233 +/- 68 sec) | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 12. | ALA4392292 | F | Antidepressant-like activity in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as immobility time at 100 ng/ml, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail suspension test (Rvb = 74.2 +/- 2.9 sec) | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 13. | ALA4392293 | F | Antidepressant-like activity in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as immobility time at 100 ng/ml, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail suspension test (Rvb = 56.5 +/- 18.8 sec) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4392295 | F | Cognition enhancing effect in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as sucrose consumption over water at 100 ng/ml, ip administered as single dose measured after 60 mins relative to control (Rvb = 0.46 +/- 0.04 No_unit) | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 15. | ALA4392296 | F | Cognition enhancing effect in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as sucrose consumption over water at 100 ng/ml, ip administered as single dose measured after 24 hrs relative to control (Rvb = 0.46 +/- 0.04 No_unit) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA4392298 | A | Plasma concentration in Slc:ICR mouse at 100 ng/g, iv measured immediately by LC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 17. | ALA4392299 | A | Half life in Slc:ICR mouse plasma during fast phase at 100 ng/g, iv measured for 15 mins by LC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 18. | ALA4392300 | A | Half life in Slc:ICR mouse plasma during slow phase at 100 ng/g, iv measured for 15 to 60 mins by LC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature | ||
| 19. | ALA4392301 | A | Plasma concentration in Slc:ICR mouse assessed as oxytocin level at 100 ng/g, iv measured within 60 mins by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 20. | ALA4392302 | A | Drug level in Slc:ICR mouse cerebrospinal fluid at 100 ng/g, iv measured after 30 mins by LC-MS/MS analysis | Mus musculus | 3 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!